Onset time of hyperkalaemia after angiotensin receptor blocker initiation: When should we start serum potassium monitoring?

Journal of Clinical Pharmacy and Therapeutics

Volumn 39, Issue 1, 2014, Pages 61-68

  Park, I W ^a   Sheen, S S ^a   Yoon, D ^a   Lee, S H ^b   Shin, G T ^a   Kim, H ^a   Park, R W ^a,c  

^a Ajou University School of Medicine   (South Korea)

^b Ajou University   (South Korea)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

adverse effects; angiotensin receptor blockers; hyperkalaemia; potassium

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIURETIC AGENT; NON POTASSIUM SPARING DIURETIC; POTASSIUM; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DIABETES MELLITUS; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HOSPITAL PATIENT; HUMAN; HYPERKALEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POTASSIUM BLOOD LEVEL; RETROSPECTIVE STUDY; RISK FACTOR; TEACHING HOSPITAL;

ADVERSE EFFECTS; ANGIOTENSIN RECEPTOR BLOCKERS; HYPERKALAEMIA; POTASSIUM;

ANGIOTENSIN RECEPTOR ANTAGONISTS; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; HYPERKALEMIA; MALE; MIDDLE AGED; POTASSIUM; RETROSPECTIVE STUDIES; RISK; RISK FACTORS;

EID: 84891829529     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12109     Document Type: Article

References (28)

1. Hemmelgarn BR, Chen G, Walker R, et al,. Trends in antihypertensive drug prescriptions and physician visits in Canada between 1996 and 2006. Can J Cardiol, 2008; 24: 507-512.
2. Taylor AA, Siragy H, Nesbitt S,. Angiotensin receptor blockers: pharmacology, efficacy, and safety. J Clin Hypertens (Greenwich), 2011; 13: 677-686.
3. Granger CB, Ertl G, Kuch J, et al,. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J, 2000; 139: 609-617.
4. Raebel MA,. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cardiovasc Ther, 2012; 30: e156-e166.
5. Sadjadi SA, McMillan JI, Jaipaul N, Blakely P, Hline SS,. A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers. Ther Clin Risk Manag, 2009; 5: 547-552.
6. Winkelmayer WC, Zhang Z, Shahinfar S, Cooper ME, Avorn J, Brenner BM,. Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes. Diabetes Care, 2006; 29: 2210-2217.
7. Investigators O, Yusuf S, Teo KK, et al,. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med, 2008; 358: 1547-1559.
8. Park I, Sheen SS, Lim HS, et al,. Comparison of hyperkalemic risk in hospitalized patients treated with different Angiotensin receptor blockers: a retrospective cohort study using a korean clinical research database. Am J Cardiovasc Drugs, 2012; 12: 255-262.
9. Raebel MA, Ross C, Xu S, et al,. Diabetes and drug-associated hyperkalemia: effect of potassium monitoring. J Gen Intern Med, 2010; 25: 326-333.
10. Bootsma JE, Warle-van Herwaarden MF, Verbeek AL, et al,. Adherence to biochemical monitoring recommendations in patients starting with renin angiotensin system inhibitors: a retrospective cohort study in the Netherlands. Drug Saf, 2011; 34: 605-614.
11. Park I, Park RW, Lim SK, et al,. Rectal culture screening for vancomycin-resistant enterococcus in chronic haemodialysis patients: false-negative rates and duration of colonisation. J Hosp Infect, 2011; 79: 147-150.
12. Park MY, Kim EY, Lee YH, et al,. Analysis of Relationship between Levofloxacin and Corrected QT Prolongation Using a Clinical Data Warehouse. Healthc Inform Res, 2011; 17: 58-66.
13. Park MY, Yoon D, Choi NK, et al,. Construction of an open-access QT database for detecting the proarrhythmia potential of marketed drugs: ECG-ViEW. Clin Pharmacol Ther, 2012; 92: 393-396.
14. Park MY, Yoon D, Lee K, et al,. A novel algorithm for detection of adverse drug reaction signals using a hospital electronic medical record database. Pharmacoepidemiol Drug Saf, 2011; 20: 598-607.
15. Sheen SS, Choi JE, Park RW, Kim EY, Lee YH, Kang UG,. Overdose rate of drugs requiring renal dose adjustment: data analysis of 4 years prescriptions at a tertiary teaching hospital. J Gen Intern Med, 2008; 23: 423-428.
16. Yoon D, Park MY, Choi NK, Park BJ, Kim JH, Park RW,. Detection of adverse drug reaction signals using an electronic health records database: Comparison of the Laboratory Extreme Abnormality Ratio (CLEAR) algorithm. Clin Pharmacol Ther, 2012; 91: 467-474.
17. Ingelsson E, Arnlov J, Sundstrom J, Lind L,. The validity of a diagnosis of heart failure in a hospital discharge register. Eur J Heart Fail, 2005; 7: 787-791.
18. Khand AU, Shaw M, Gemmel I, Cleland JG,. Do discharge codes underestimate hospitalisation due to heart failure? Validation study of hospital discharge coding for heart failure. Eur J Heart Fail, 2005; 7: 792-797.
19. Kumler T, Gislason GH, Kirk V, et al,. Accuracy of a heart failure diagnosis in administrative registers. Eur J Heart Fail, 2008; 10: 658-660.
20. Quach S, Blais C, Quan H,. Administrative data have high variation in validity for recording heart failure. Can J Cardiol, 2010; 26: 306-312.
21. Reid AY, St.Germaine-Smith C, Liu M, et al,. Development and validation of a case definition for epilepsy for use with administrative health data. Epilepsy Res, 2012; 102: 173-179.
22. Ray WA,. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol, 2003; 158: 915-920.
23. de Denus S, Tardif JC, White M, et al,. Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials. Am Heart J, 2006; 152: 705-712.
24. Muzzarelli S, Maeder MT, Toggweiler S, et al,. Frequency and predictors of hyperkalemia in patients >/=60 years of age with heart failure undergoing intense medical therapy. Am J Cardiol, 2012; 109: 693-698.
25. Shlipak MG,. Pharmacotherapy for heart failure in patients with renal insufficiency. Ann Intern Med, 2003; 138: 917-924.
26. Palmer BF,. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med, 2004; 351: 585-592.
27. Perazella MA,. Drug-induced hyperkalemia: old culprits and new offenders. Am J Med, 2000; 109: 307-314.
28. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med, 1991; 325: 293-302.